02/10/2026 Biogen reported 52-week Phase 2 data for litifilimab in CLE Biogen reported 52-week Phase 2 data for litifilimab in CLE (Ref) Biogen reported 52-week results from the Phase 2 portion (Part A) of the ongoing Phase 2/3 AMETHYST study of litifilimab (BIIB059; anti-BDCA2 mAb) showing continued improvement in cutaneous lupus erythematosus (CLE). 27.2% of patients achieved clear or almost clear skin (CLA-IGA 0–1) at Week 52, while 28.8% achieved CLASI-70. Patients who